In particular, TCL+TIO3 not only induced the activation of CD4+ T, CD8+ T and NK cells but also inhibited PD1 and PD-L1 expression in multiple immune cells and glioma tissues by suppressing the expression of TGF-β2. The gene discussed is CD4; the disease is glioma.